Starling Oncology runs community-based cancer clinics, delivering chemotherapy, infusions, and clinical trials directly to patients outside big hospitals. Think of it as a neighborhood chain of cancer-care centers that also manages the business side of treatme
Revenue runs about USD 0.50B annually, but the company loses money—net income is negative USD 0.06B, with a thin 15.2% gross margin and a -12.1% net margin. The model leans on volume and value-based contracts, but it's not yet profitable, so cash burn is the k
The moat is weak. Community oncology faces intense competition from hospital systems like HCA Healthcare and large national chains like OneOncology, which can undercut on price and scale. No proprietary tech or exclusive contracts protect Starling, so patients
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
